Trials / Completed
CompletedNCT00646542
Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency
A Multi-center, Randomized, Double-blind Clinical Trial to Evaluate the Safety and Tolerability of 24 Weeks Treatment With (50 mg qd) Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 525 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This clinical trial is designed to provide additional information on the safety and tolerability of vildagliptin (50 mg once daily (qd)) when used in patients with type 2 diabetes mellitus (T2DM) and moderate or severe renal insufficiency.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vildagliptin | |
| DRUG | Placebo |
Timeline
- Start date
- 2005-03-01
- Primary completion
- 2010-10-01
- First posted
- 2008-03-28
- Last updated
- 2020-12-17
Locations
12 sites across 12 countries: Argentina, Australia, Canada, Costa Rica, Finland, France, Germany, India, Norway, Russia, Spain, Sweden
Source: ClinicalTrials.gov record NCT00646542. Inclusion in this directory is not an endorsement.